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Abstract: The frequent coexistence of depression in epileptic patients raises the issue of 
simultaneous use of antidepressants along with antiepileptic drugs in the management of such 
cases. However, it is necessary to evaluate the safety of these antiepileptic/antidepressant 
drug combinations. The present study investigates the effect of the antidepressant paroxetine 
(a selective serotonin reuptake inhibitor) administered alone or in combination with the anti-
epileptic drug sodium valproate on chemoconvulsions induced by picrotoxin (PTX). Seizure 
score was recorded in vivo, and the levels of thiobarbituric acid-reactive substances and gamma 
aminobutyric acid (GABA) were measured in the nucleus accumbens of the tested groups of 
mice. The results show enhancement of seizure severity with significant reduction in GABA 
levels upon PTX treatment that were reversed by its combination with sodium valproate. On the 
other hand, paroxetine administered in combination with sodium valproate provided significant 
protection against PTX-induced convulsions as well as a significant increase in GABA levels in 
selected brain areas. These results favor their application in management of epilepsy-depression 
comorbidities.
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Introduction
Epilepsy is one of the most common neurological disorders characterized by recur-
ring excessive neuronal discharge, exhibited by transient episodes of motor, sensory, 
or psychic dysfunction, with or without unconsciousness or convulsive movements. 
In addition, epilepsy may be associated with neurodegeneration, presumably due to 
abnormal lipid peroxidation.1,2 On the other hand, comorbid depression is common 
in patients with epilepsy. A review of available studies3 suggested a high prevalence 
of mood (affective) disorders, especially major depression (8%–48%), followed by 
anxiety (5%–32%), in patients with epilepsy. Although the mechanisms underlying 
the epilepsy-depression relationship have not been clearly identified, depression in 
epileptic cases is multifaceted with many interacting neurobiological and psychosocial 
determinants. These include clinical features of epilepsy (seizure frequency, type, foci, 
or lateralization of foci) and neurochemical or iatrogenic mechanisms.4,5
Serotonin and norepinephrine are the most studied neurotransmitters in mood 
  disorders. A decrease in the functional activity of central serotonergic and cate-
cholaminergic systems is probably associated in major depressive episodes.6   Applying 
an appropriate strategy with drugs targeting both neurotransmitter systems may improve 
the efficacy of the antidepressant treatment. Antidepressant drugs are either selective 
serotonin reuptake inhibitors (SSRIs), eg, paroxetine, or mixed serotonin/noradrenaline 
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reuptake inhibitors (SNRIs), eg, venlafaxine and duloxetine.7,8 
SSRIs, such as paroxetine and citalopram, are effective in 
treating depressed patients.9,10 However, other neurotrans-
mitter systems may also be involved in the pathogenesis of 
depression as a gamma aminobutyric acid (GABA)ergic 
system that is considered to be implicated in the pathogenetic 
mechanisms of mood disorders.11
The high prevalence of depression in epileptic patients 
may necessitate the addition of an antidepressant agent in 
therapy. However, the use of antidepressant drugs in epi-
leptics has been a matter of debate for clinicians because 
of reports that these drugs may have frank convulsant or 
proconvulsant effects that increase seizure incidence.12 This 
might happen due to modulation of pre- and/or postsynaptic 
receptor function and rate of release of neurotransmitters 
such as γ-amino butyric acid, noradrenaline, dopamine, 
or serotonin,13,14 so it is important to recognize and assess 
possible implications of antiepileptic/antidepressant drug 
combinations in the management of epileptic cases compli-
cated by depression.
The rationale of the present study is to (1) evaluate the 
seizure score of the antiepileptic drug sodium valproate 
with the antidepressant paroxetine in the management of 
chemically induced seizures in chronically restrained mice, 
and (2) study the effect of these drug combinations on thio-
barbituric acid-reactive substances (TBARS) as a marker of 
lipid peroxidation and GABA levels in nucleus accumbens 
in tested mice.
Materials and methods
Drugs and chemicals
Picrotoxin (PTX; Sigma-Aldrich Co, St Louis, MO), 
  paroxetine HCl (GlaxoSmithKline, Brentford, Middlesex, 
UK), sodium valproate (2-propyl pentanoic acid-Na salt; 
Sigma-Aldrich Co), GABA and L-norvaline standards 
(Sigma-Aldrich Co), ethanol (high-performance liquid chro-
matography [HPLC] grade; Merck and Co, Inc, Whitehouse 
Station, NJ), triethylamine (Merck and Co, Inc), phenyliso-
thiocyanate (PITC; Sigma-Aldrich Co), hydrochloric acid 
(32%, Merck and Co, Inc), acetonitrile (Merck and Co, Inc), 
glacial acetic acid (Sigma-Aldrich Co), and sodium acetate 
anhydrous (Merck and Co, Inc).
Animals
Albino mice (20–25 g) were divided into four groups with 
12 mice each. They were housed in cages with a natural 
light-dark cycle and fed on a standard pellet diet and water 
ad libitum.
Picrotoxin-induced convulsions
All mice were given a single subcutaneous dose (3.5 mg/kg 
body weight) of PTX either in the absence of any treatment 
(control group) or following administration of a single dose 
of the test drug(s) (treated groups). Accordingly, the study 
comprised the following four groups:
1.  Control group receiving neither antiepileptic nor 
  antidepressant treatment.
2.  Sodium valproate-treated group: received sodium 
  valproate dissolved in water (30 mg/kg body weight 
intraperitoneal) per Siddiqui, A et al 15
3.  Paroxetine-treated group: was administered paroxetine 
dissolved in saline (1 mg/kg body weight intraperitoneal). 
This dose was selected according to David, D et al.16
4.  Sodium valproate/paroxetine-treated group: given sodium 
valproate and paroxetine treatment in doses of 30 mg/kg 
body weight intraperitoneal and 1 mg/kg body weight 
intraperitoneal, respectively.
In the treated groups, PTX was injected after a suitable 
latency corresponding to the time expected to reach a peak 
effect following administration of the respective test drug(s). 
The latency of both tested drugs was estimated to be 1 hour 
after their intraperitoneal administration, as determined by 
the pilot study.
Immediately after administration of PTX, the animal 
was observed for 30 minutes. The onset of convulsive 
behavior as well as the nature and severity of convulsions 
were carefully recorded using the scoring system 1–7 as 
follows: hyperlocomotion or piloerection (erection of the 
skin hair), 1; stunning (immobile) or catatonic posture 
(assuming a fixed posture and inability to move), 2; clonic 
body tremors (a series of involuntary muscular contrac-
tions due to sudden stretching of the muscle), 3; prolonged 
clonic tremors, 4; tonic forelimb convulsions followed by 
clonus, 5; repetitive tonic (prolonged muscular   contraction) 
forelimb convulsions followed by clonus, 6; and tonic 
extension of both forelimbs and hindlimbs followed by 
clonus, 7; a mean cumulative score was calculated for each 
treatment group for comparisons and statistical analysis. 
At the end of the PTX study for each group, the animals 
were returned to their cages to continue with the chronic 
restraint stress study.
Chronic restraint stress procedure
Each mouse of the respective group was placed in a wire 
mesh restrainer 6 hours daily for 21 days. At the end of the 
restraint period, the mice were moved to their cages.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2584
KamalInternational Journal of Nanomedicine 2012:7
Measurement of nucleus accumbens TBArS  
as a marker of lipid peroxidation
At the end of the 21 days of restraint stress, nucleus accum-
bens was excised out of the brain and rinsed with cold 
0.14 M NaCl, and part of it was homogenized in 25% ice 
cold 50 mM Tris-HCl buffer, pH 7.4.17 One hundred and fifty 
microliters of the tissue supernatant of samples was diluted 
to 500 µL with deionized water. A total of 250 µL of 1.34% 
thiobarbituric acid was added to all the tubes, followed by 
the addition of an equal volume of 40% trichloroacetic acid. 
The mixture was shaken and incubated for 30 minutes in a 
boiling water bath. Tubes were allowed to cool to room tem-
perature and the absorbance was read at 532 nm using zero 
concentration as blank.18
Determination of gABA in homogenates of nucleus 
accumbens isolated from tested mice
The GABA level in the tissue homogenates of the nucleus 
accumbens was determined.8,19–21 The HPLC method with pre-
column PITC derivatization was used for the determination of 
GABA levels in the homogenate of the nucleus accumbens 
of the brains of mice of different groups. The measurement 
scale of the data was in nmol/mg tissue protein.
Parts of the homogenates of nucleus accumbens were 
centrifuged in a cooling (4°C) centrifuge at 15,000 rpm for 
10 minutes. The supernatant was aspirated and transferred to 
an Eppendorff tube, while the pellet was kept at -70°C until 
assayed for its total protein content.22 According to Gunawan 
et al,19 each sample was derivatized via drying 100 µL of the 
aspirated supernatant in the centrivap, under vacuum. The 
residue was dissolved in 20 µL of ethanol-water-  triethylamine 
(2:2:1) and evaporated to dryness under vacuum. A 30 µL 
mixture of ethanol-water-triethylamine-PITC (7:1:1:1) was 
added to the residue and allowed to react for 20 minutes at 
room temperature to form the PITC derivatives of the amino 
acids. Excess reagent was then evaporated under vacuum. 
The mobile phase of HPLC consisted of solvents A and B: 
solvent A: 0.1 M sodium acetate buffer (pH = 5.8), solvent 
B: acetonitrile: water (60:40, v:v). A mixture of 80%   solvent 
A and 20% solvent B was adjusted for the “isocratic” HPLC 
separations. Flow rate was set at 0.6 mL/minutes. The injected 
sample was 20 µL. The peaks were detected at 254 nm wave 
length. Standard curves for GABA and norvaline were plotted 
using norvaline 2 nmol/20 µL as an internal standard. The 
ratio of the peak area of each concentration of each standard 
to the peak area of the internal standard was determined and 
entered against the concentration of the standard, in a simple 
regression procedure.
Protein determination
The total protein content of nucleus accumbens homogenate 
was determined.22
Data analysis
The results were presented as medians with 25 and 
75 percentiles for seizure score and mean ± standard deviation 
for seizure onset. Additionally, the contents of TBARS as a 
marker of lipid peroxidation and GABA in nucleus accumbens 
of tested mice of all groups were expressed in nmol/mg tis-
sue protein as mean ± standard deviation. Data were analyzed 
using one-way analysis of variance with Tukey t-test at a 95% 
confidence level with significant differences between groups 
at P , 0.05.
Results
Effect of different drug treatment 
regimens on PTX-induced convulsions
Single sodium valproate treatment significantly (P , 0.05) 
delayed the onset and reduced the severity of PTX-induced 
convulsions compared with the control group. On the 
other hand, treatment with paroxetine alone significantly 
(P , 0.05) delayed the onset and reduced the severity of 
convulsions compared with the control group. However, 
it was significantly (P , 0.05) less effective than single 
sodium valproate treatment with respect to prolonging onset 
latency or reducing severity of convulsions. Treatment with 
both drugs significantly (P , 0.05) delayed the onset and 
reduced the severity score of convulsions in comparison with 
all other groups (Table 1).
Effect of tested drugs on TBArS  
in nmol/mg tissue protein in nucleus 
accumbens of mice exposed  
to chronic restraint model
Sodium valproate administration to group 2 significantly 
(P , 0.05) lowered TBARS level compared with the control 
group. Coadministration of paroxetine with sodium valproate 
significantly (P , 0.05) reduced TBARS level compared 
with the control, sodium valproate, or paroxetine groups 
(Figure 1).
Effect of tested drugs on the gABA level 
in the nucleus accumbens of tested mice
Sodium valproate administration to group 2 significantly 
(P , 0.05) increased GABA level compared with the con-
trol group. Coadministration of paroxetine with sodium 
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Table 1 Effect of different drug treatment regimens on picrotoxin (PTX)-induced convulsions
Group Treatment Dose  
(mg/kg)
Onset of convulsions  
(seconds)
Severity (score range 1–7)
25% Median 75%
1 PTX (sc) 3.5 449.2 ± 26.24 5 5 5
2 Sodium valproate (ip) 50 1408 ± 79.95a 1 1a 2
3 Paroxetine (ip) 2.5 714.8 ± 22.92a 3 4 4
4 Sodium valproate + paroxetine (ip) 50 + 8 1724 ± 52.65a,b 1 1a 1
Notes: Modulation of onset and severity of PTX-induced convulsions in mice treated with either sodium valproate or paroxetine (groups 2 and 3), while in group 4 
paroxetine was given in combination with sodium valproate. Treatment with sodium valproate significantly (P , 0.05) delayed onset of convulsions and reduced their 
severity score compared with the control group. On the other hand, single treatment with paroxetine significantly (P , 0.05) delayed onset of convulsions compared with 
the control group, and when combined with sodium valproate it further significantly (P , 0.05) reduced the convulsion severity score compared with the other groups. 
aP , 0.05 compared with control group; bP , 0.05 compared with sodium valproate group.
Abbreviations: ip, intraperitoneal; sc, subcutaneous.
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Figure 1 Effect of tested drugs on thiobarbituric acid-reactive substances (TBArS) 
in nmol/mg tissue protein in nucleus accumbens of mice exposed to a chronic 
restraint model. 
Notes:  Changes  in  cortical  TBArS  levels  upon  treatment  with  either  sodium 
valproate or paroxetine given alone or in combination with each other. Administration 
of sodium valproate resulted in a significant (P , 0.05) reduction in the TBArS 
content of nucleus accumbens compared with groups 1 and 3, while paroxetine in 
combination with sodium valproate (group 4) significantly reduced TBARS content 
when compared with either the valproate-only treated group or the paroxetine-
treated  group  (groups  2  and  3).  *P  ,  0.05  significant  decrease  compared  with 
groups 1 and 3; **P , 0.05 significant increase compared with groups 2 and 4.
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Figure 2 Effect of tested drugs on the gamma aminobutyric acid (gABA) level in the 
nucleus accumbens of tested mice. 
Note: Sodium valproate significantly (P , 0.05) increased the gABA concentration 
in  the  nucleus  accumbens  of  mice  of  group  2  compared  with  group  1.  gABA 
concentration of chronic mild stress mice was significantly increased (P , 0.05) 
by  both  sodium  valproate  and  paroxetine  compared  with  all  tested  groups. 
*P , 0.05 significant increase compared with groups 1 and 3.
valproate significantly (P , 0.05) increased GABA level if 
compared with the control, sodium valproate, or paroxetine 
groups (Figure 2).
Discussion
The high incidence of psychiatric comorbidities, especially 
depression and anxiety, seen in epileptic patients may require 
treatment of both disorders at the same time with a combina-
tion of antiepileptic and psychotropic drugs. Therefore, the 
safety of these drug combinations should be evaluated in 
order to optimize the treatment of epilepsy. Interestingly, 
some antiepileptic drugs have a complex of proconvulsant 
and anticonvulsant activities.23 On the other hand, although 
the risk of antidepressant-induced seizures, in general, 
is very low, most, if not all, antidepressant agents have 
a propensity to lower the seizure threshold, and most are 
associated with a clinical risk of seizures. The mechanism 
by which antidepressants cause seizures, however, is still 
not well established. Recently, it has been suggested that the 
proconvulsant effects of antidepressants may be attributed 
to their local anesthetic, antimuscarinic, or anti-histaminic 
properties.20
Although many studies report that use of older antidepres-
sants, eg, monoamine oxidase inhibitors and tricyclic antide-
pressants, is frequently associated with the risk of seizures,24,25 
the newer antidepressants, eg, SSRIs and SNRIs, are claimed 
to exhibit a better tolerability profile for most patients. 
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The safety of such agents should still be thoroughly assessed 
for clinical application in epileptic cases.
There is great debate about the use of SSRIs in the man-
agement of depression complicating epileptic cases. There 
are old reports about the increase in seizure frequency and 
intensity by SSRIs.26,27 Surprisingly, though the reports about 
proconvulsive actions of SSRIs are ever increasing, these 
agents are still widely used in epileptics to treat accompany-
ing depression.28
Meanwhile, there is rising interest to study the possible 
mechanism of action of many antidepressants on GABA. 
This amino acid is the major inhibitory neurotransmitter in 
the brain that diminishes the activity of its target neurons. 
It also modulates the activity of several neurotransmitters, 
including dopamine, serotonin, and norepinephrine. It is 
synthesized in a single step from its precursor glutamate 
by glutamic acid decarboxylase and metabolized by 
successive transamination and oxidation to yield suc-
cinic semialdehyde and succinic acid, respectively. As 
part of the transamination reaction, a recycling system 
is formed in which α-ketoglutaric acid is converted to 
the GABA precursor glutamate by GABA-glutamic acid   
transaminase.29
The cornerstone of the GABA hypothesis of bipolar 
disorder is that GABA provides an inhibitory action to 
both norepinephrine and dopamine systems.30 Although 
this widely expressed neurotransmitter has been thought to 
exert a tonic inhibitory effect on norepinephrine systems, 
an earlier study31 suggests that GABA may in fact facili-
tate norepinephrine activity. It also reported that plasma 
GABA levels are relatively reduced in depressed patients. 
The current theory of GABA and depression is that low 
plasma levels of GABA may identify an inheritable ten-
dency for mood disorders such as depression or bipolar 
disease.32 Hence, the role of GABA in mood disorders and 
its interactions with serotonin and norepinephrine systems 
is worthy of further study. The present study investigated 
the alterations of GABA content in the nucleus accumbens 
of chronic restrained mice exposed to a chemoconvulsive 
substance (PTX) and treated by sodium valproate and/or 
paroxetine.
Additionally, the models of chemoconvulsion and 
chronic restraint used in this study evaluate the effect of 
paroxetine used alone or in combination with a widely used 
antiepileptic drug sodium valproate on seizure threshold 
and also on an oxidative stress marker, namely TBARS. The 
results indicate that sodium valproate alone significantly 
attenuated PTX-induced convulsions, decreased TBARS 
levels, and increased GABA contents in nucleus accumbens 
of tested mice. This may be attributed to an inhibitory effect 
of sodium valproate on dopamine-induced hyperactivity in 
nucleus accumbens. This inhibitory effect is similar to that 
by GABA to control dopaminergic function in this area of the 
brain. Additionally, this antiepileptic drug has been shown 
to inhibit the activity of succinic semialdehyde dehydroge-
nase and GABA transaminase enzymes involved in GABA 
metabolism. This action will result in an elevation of GABA 
content. PTX, the GABA antagonist, when injected prior 
to valproate blocked the reduction in locomotor activity 
caused by valproate. This further supports the hypothesis 
that the effects of valproate are mediated by the stimulation 
of GABA receptors.33
The oxidative stress and modulation of antioxidant 
enzyme activity may contribute to the central deleterious 
consequences of chronic stress.34,35 One of the neurochemi-
cal complications associated with epilepsy is increased 
lipid peroxide levels, especially TBARS, in the brain.36   
Enhanced lipid peroxidation can induce seizure activity by 
direct activation of glutamine synthase, thereby permitting 
an abnormal buildup of the excitatory neurotransmitter 
glutamic acid.37
A single-blind, placebo-controlled, crossover trial38   
demonstrated a beneficial combination of paroxetine and 
other antiepileptic drugs. The authors investigated pos-
sible interactions between paroxetine, a serotonin reuptake 
inhibitor, and carbamazepine, valproate, and phenytoin. It 
was carried out in 20 outpatients with epilepsy. Patients 
on long-term treatment with carbamazepine, valproate, or 
phenytoin were given a 7-day placebo treatment, followed 
by paroxetine cotreatment for 16 days. Side effects were 
infrequent and mild. None of the patients experienced 
epileptic seizures during this clinical study. These results 
support findings of paroxetine in this experimental research. 
Its beneficial effect, when combined with valproate, could be 
related to a significant reduction in TBARS and a significant 
increase in GABA contents in crucial brain areas such as 
nucleus accumbens.
Preliminary findings of clinical studies, demonstrated in 
a report of the American Neuropsychiatric Association Com-
mittee on Research, denoted some neuroprotective effects of 
drugs, eg, paroxetine and valproic acid, in neurodegenerative 
diseases. A recommendation was reported by these studies 
to perform further clinical drug trials on the use of these 
well-known medications, not only for their psychotropic 
effects but also for neuroprotection in neurodegenerative 
diseases.39
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Conclusion
In conclusion, the management of epilepsy is a difficult 
task when associated with other neuropsychiatric disorders. 
Therefore, extreme caution should be exercised with respect 
to selection of the proper antidepressants to treat epilepsy-
depression comorbidities. The SSRI paroxetine could be rec-
ommended in the management of such cases, in combination 
with sodium valproate, as it may reduce seizure frequency 
and intensity most likely as a result of decreased brain levels 
of the oxidative stress marker TBARS with an increase in 
GABA content of nucleus accumbens of mice exposed to a 
chemoconvulsive model.
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